Currently, China's innovative drug industry is integrating into the global pharmaceutical innovation system with strong momentum. From being dominated by generic drugs ten years ago to now accounting for a significantly increased proportion in global

At the recently held 10th Pharmaceutical Innovation and Investment Conference, reporters from Securities Daily conducted interviews with several leading figures in the pharmaceutical industry to decode the breakthrough path and long-distance journey

Multi-factor Promotion of Industrial Upgrading

Most Chinese biotech companies were focused on generic drug research and development ten years ago. Today, more and more large international biotech companies are actively seeking opportunities to collaborate on innovative treatments in China.

According to a research report by China Post Securities, China's share of projects in global innovative drug business cooperation and expansion (BD) transactions has rapidly increased from 3% in 2019 to 13% in 2024. The proportion of transaction amou

According to IQVIA data, Chinese and multinational pharmaceutical companies reached 61 cooperation agreements in the first half of 2025. Specifically, the total transaction value targeting China's local assets continued to climb, reaching $48.5 billi

"As of October, the total amount of BD transactions for innovative drugs in China has exceeded 100 billion US dollars in 2025, with single transaction sizes repeatedly setting new records. The continued expansion of BD transactions reflects global re

"China's pharmaceutical industry has been at the forefront of Asia, and even the world, in many aspects. From being a 'follower' in the past to now being a 'parallel runner', and even achieving 'leadership' in some fields.' This is what Qin Shukui, t

In the field of oncology, Qin Shukui said that in recent years, the country has attached great importance to people's health and the development of tumor prevention and research. The policy has greatly helped to improve the clinical level.

"The driving forces for the upgrade and sustainable development of China's biopharmaceutical industry are mainly embodied in three aspects: first, the adjustment of 'eliminating generic drugs and promoting innovative drugs' and the huge market demand

The enormous changes in China's innovative drugs in the past ten years are inseparable from the investment of hundreds of billions of investment funds. Innovation must be driven by both talent and capital, and both are indispensable in the developmen

This year, pharmaceutical companies have flocked to list in Hong Kong, with many newly listed drug companies showing strong stock performance on their first day. As an example, on April 15th, Ying En Biotech, a prominent antibody-drug conjugate (ADC)

Going abroad continues to maintain a positive trend

China's innovative drugs are increasingly heading overseas, with more and more companies exploring global markets through diversified channels and building their own discourse system on the international stage based on their independent research and

Founded in 2014, Silver Pharmaceutical is a science-driven biopharmaceutical company focusing on the field of metabolic diseases. In January 2025, Silver Pharmaceutical's self-developed class I innovative drug, Isupaglutide α (trade name: Yinoqing),

"Clinical research shows that ispaglulide α has good safety and excellent hypoglycemic and weight-loss effects, and demonstrates significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver disease. Current

When it comes to the topic of innovative drug companies going global, Zhang Lianshan, Director and Executive Vice President of Hengrui Pharmaceutical, told reporters, Hengrui is promoting innovative drugs to go global through both 'riding on others'

In 2022, Hualien Pharmaceutical's dulaglutide tablets (trade name: Huatangning) received approval for market launch, becoming the world's first new hypoglycemic drug of glucose kinase activator (GKA) category.

Chen Li, CEO of Huailing Pharmaceutical, shared with reporters the company's research experience on the world's first innovative drug, dulegetide: The development of innovative drugs is essentially a breakthrough from '0' to '1'. Taking glucokinase a

Source: Securities Daily